Breaking News Instant updates and real-time market news.

RVNC

Revance

$17.91

0.05 (0.28%)

, AGN

Allergan

$184.95

-0.43 (-0.23%)

21:10
12/01/19
12/01
21:10
12/01/19
21:10

Revance initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Terence Flynn initiated coverage of Revance Therapeutics (RVNC) with a Buy rating and $25 price target. The company is is developing DaxibotulinumtoxinA, an injectable botulinum toxin that would compete with Allergan's (AGN) Botox and other smaller players in the $4B-plus global neuromodulator market, Flynn tells investors in a research note. Revance is requesting a six month duration versus three-to-four months for currently marketed neurotoxins, which will be a key point of differentiation, adds the analyst.

RVNC

Revance

$17.91

0.05 (0.28%)

AGN

Allergan

$184.95

-0.43 (-0.23%)

  • 03

    Dec

RVNC Revance
$17.91

0.05 (0.28%)

08/06/19
HCWC
08/06/19
NO CHANGE
HCWC
Buy
Revance filing for Daxi appears 'imminent,' says H.C. Wainwright
After Revance reported Q2 results, H.C. Wainwright analyst Douglas Tsao noted that the company indicated, "most importantly," that it is on track to file the BLA for Daxi for the treatment of glabellar lines this fall. There had been some investor concern after the filing had been delayed, but now that it appears 'imminent,' investors can again focus on Daxi's "significant" commercial potential, said Tsao, who reiterates a Buy rating on Revance shares.
10/14/19
STFL
10/14/19
NO CHANGE
STFL
Buy
Stifel surprised by CEO exit, but remains 'optimistic' on Revance
Stifel analyst Annabel Samimy maintained a Buy rating and $50 price target on Revance following the "sudden board-led removal of Dan Browne," which was "due to issues unrelated to performance." In a research note titled 'CEO Departure Surprising, but Strategic Plans Continue,' the analyst said she remained "optimistic" on the company and its new CEO, Mark Foley, the former CEO of Zeltiq Aesthetics, who "provides aesthetics expertise and understanding of the company's therapeutics strategic plan."
10/30/19
WELS
10/30/19
UPGRADE
WELS
Outperform
Revance upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo upgraded Revance to Outperform from Market Perform.
10/30/19
WELS
10/30/19
UPGRADE
Target $20
WELS
Outperform
Wells Fargo upgrades Revance to Outperform, boosts target to $20
Wells Fargo analyst Jacob Hughes upgraded Revance Therapeutics (RVNC) to Outperform from Market Perform with a price target of $20, up from $12.50. After meeting with management, the analyst likes the setup for shares. Revance has a commercial-focused CEO with a history of shareholder value creation in aesthetics and a "catalyst rich" 12 months, Hughes tells investors in a research note. He believes the stock has "significant upside potential" and likes the cash pay nature of aesthetics. The multi-billion neurotoxins market will continue to expand, and disruption from the Allergan (AGN), AbbVie (ABBV) merger will create opportunities for Revance to take share, contends Hughes.
AGN Allergan
$184.95

-0.43 (-0.23%)

11/19/19
UBSW
11/19/19
DOWNGRADE
Target $203
UBSW
Neutral
Allergan downgraded to Neutral from Buy at UBS
UBS analyst Navin Jacob downgraded Allergan to Neutral from Buy with a $203 price target.
11/19/19
UBSW
11/19/19
DOWNGRADE
Target $203
UBSW
Neutral
UBS downgrades Allergan to Neutral ahead of expected deal closure
UBS analyst Navin Jacob downgraded Allergan (AGN) to Neutral from Buy with a price target of $203, up from $189. Based on takeover terms and a $96 price target for AbbVie (ABBV), much of the upside is largely baked in to Allergan shares, Jacob tells investors in a research note. The analyst expects the deal to close in Q1 of 2020 and believes that the companies have sufficiently addressed possible anti-trust issues with the announced divestitures of Zenpep and Brazikumab.
11/20/19
SBSH
11/20/19
NO CHANGE
Target $98
SBSH
Buy
AbbVie price target raised to $98 from $90 at Citi
Citi analyst Andrew Baum raised his price target for AbbVie (ABBV) to $98 from $90 and keeps a Buy rating on the shares. The analyst believes AbbVie will trade near-term above its $92 intrinsic value as Skyrizi and Rinvoq forecasts are revised upwards. In the near-term, the market will likely choose to focus on ongoing Skyrizi upgrades and Allergan (AGN) synergies and disregard mid and long-term risks to chronic lymphocytic leukemia estimates, Baum tells investors in a research note. The analyst's "bull-case valuation" is $119 per share.

TODAY'S FREE FLY STORIES

BILL

Bill.com

$0.00

(0.00%)

23:41
12/11/19
12/11
23:41
12/11/19
23:41
Syndicate
Bill.com 9.824M share IPO priced at $22.00 »

The deal size was raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FTSV

Forty Seven

$36.00

1.4 (4.05%)

23:39
12/11/19
12/11
23:39
12/11/19
23:39
Syndicate
Forty Seven 4.86M share Spot Secondary priced at $35.00 »

Morgan Stanley and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NCR

NCR Corp.

$32.60

0.16 (0.49%)

20:34
12/11/19
12/11
20:34
12/11/19
20:34
Hot Stocks
NCR enters consent decree to resolve claims related to Kalamazoo River matter »

NCR Corporation announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CIEN

Ciena

$35.45

0.75 (2.16%)

, LOVE

Lovesac

$14.49

0.05 (0.35%)

20:25
12/11/19
12/11
20:25
12/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CIEN

Ciena

$35.45

0.75 (2.16%)

LOVE

Lovesac

$14.49

0.05 (0.35%)

VERU

Veru

$2.47

0.17 (7.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 17

    Dec

  • 19

    Dec

CHEF

Chefs' Warehouse

$35.51

-0.06 (-0.17%)

20:24
12/11/19
12/11
20:24
12/11/19
20:24
Initiation
Chefs' Warehouse initiated at Piper Jaffray »

Chefs' Warehouse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HSBC

HSBC

$37.15

0.44 (1.20%)

20:13
12/11/19
12/11
20:13
12/11/19
20:13
Upgrade
HSBC rating change at BofA/Merrill »

HSBC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLCE

Children's Place

$54.36

-16.31 (-23.08%)

19:54
12/11/19
12/11
19:54
12/11/19
19:54
Downgrade
Children's Place rating change at Wedbush »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LVGO

Livongo Health

$27.55

1.48 (5.68%)

19:43
12/11/19
12/11
19:43
12/11/19
19:43
Syndicate
Livongo Health 2.78M share Secondary priced at $27.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CVX

Chevron

$116.22

-1.68 (-1.42%)

19:42
12/11/19
12/11
19:42
12/11/19
19:42
Periodicals
Chevron said to be close to approving Gulf of Mexico project, Bloomberg says »

Bloomberg's Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$233.00

0.03 (0.01%)

19:27
12/11/19
12/11
19:27
12/11/19
19:27
Hot Stocks
RH CEO sold 500,000 common shares of company from Dec 9 through Dec 11 »

RH announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$47.74

0.18 (0.38%)

19:17
12/11/19
12/11
19:17
12/11/19
19:17
Hot Stocks
Crowdstrike CFO sells 215K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 09

    Dec

GLD

SPDR Gold Shares

$138.94

0.98 (0.71%)

19:00
12/11/19
12/11
19:00
12/11/19
19:00
Hot Stocks
SPDR Gold Shares holdings rise to 886.22MT from 885.93MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$147.70

1.58 (1.08%)

, GOOG

Alphabet

$1,345.14

0.64 (0.05%)

18:59
12/11/19
12/11
18:59
12/11/19
18:59
Periodicals
Disney Plus was Google's most searched term in U.S. this year, TechCrunch says »

In the United States in…

DIS

Disney

$147.70

1.58 (1.08%)

GOOG

Alphabet

$1,345.14

0.64 (0.05%)

GOOGL

Alphabet Class A

$1,344.65

1.61 (0.12%)

AAPL

Apple

$270.71

2.09 (0.78%)

T

AT&T

$38.17

0.1 (0.26%)

NFLX

Netflix

$299.25

6.04 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

, FORM

FormFactor

$23.77

0.57 (2.46%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: DLH…

DLHC

DLH Holdings

$4.58

0.525 (12.96%)

FORM

FormFactor

$23.77

0.57 (2.46%)

LULU

Lululemon

$233.31

3.75 (1.63%)

NX

Quanex

$19.72

0.68 (3.57%)

TLRD

Tailored Brands

$4.85

-0.42 (-7.97%)

NDSN

Nordson

$167.44

1.69 (1.02%)

MESA

Mesa Air

$9.25

0.17 (1.87%)

OXM

Oxford Industries

$74.07

-1.89 (-2.49%)

AKTS

Akoustis

$7.60

0.11 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 18

    Dec

TTD

Trade Desk

$250.44

0.13 (0.05%)

18:57
12/11/19
12/11
18:57
12/11/19
18:57
Hot Stocks
Trade Desk CEO: We don't own any media »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$165.20

0.37 (0.22%)

18:45
12/11/19
12/11
18:45
12/11/19
18:45
Hot Stocks
Ferrari enters into new EUR 350M credit facility »

Ferrari announces that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIBT

RiceBran

$2.09

-0.105 (-4.79%)

18:43
12/11/19
12/11
18:43
12/11/19
18:43
Syndicate
RiceBran offers to sell common stock, no amount given »

Lake Street Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$151.00

2.27 (1.53%)

, TSLA

Tesla

$352.40

3.58 (1.03%)

18:42
12/11/19
12/11
18:42
12/11/19
18:42
Hot Stocks
VMware's Poonen: Our networking business is on fire »

In an interview on…

VMW

VMware

$151.00

2.27 (1.53%)

TSLA

Tesla

$352.40

3.58 (1.03%)

DELL

Dell Technologies

$47.73

0.37 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 07

    Jan

  • 08

    Jan

  • 09

    Jan

  • 27

    Feb

SMTC

Semtech

$47.36

0.48 (1.02%)

18:38
12/11/19
12/11
18:38
12/11/19
18:38
Hot Stocks
Semtech director sells 19.3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CS

Credit Suisse

$12.95

-0.115 (-0.88%)

18:29
12/11/19
12/11
18:29
12/11/19
18:29
Periodicals
Former Credit Suisse JV exec claims she was put under surveillance, WSJ says »

Colleen Graham, a former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PANW

Palo Alto Networks

$226.76

1.71 (0.76%)

18:22
12/11/19
12/11
18:22
12/11/19
18:22
Hot Stocks
Palo Alto Networks CEO: No systematic problem with our sales »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

PBYI

Puma Biotechnology

$8.71

0.24 (2.83%)

18:08
12/11/19
12/11
18:08
12/11/19
18:08
Hot Stocks
Puma Biotechnology presents Phase II results of neratinib in breast cancer »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTHX

G1 Therapeutics

$23.06

-0.18 (-0.77%)

18:05
12/11/19
12/11
18:05
12/11/19
18:05
Hot Stocks
G1 Therapeutics presents data from Phase 1b/2a trial of lerociclib at SABCS »

G1 Therapeutics reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NH

NantHealth

$0.86

-0.0225 (-2.54%)

18:01
12/11/19
12/11
18:01
12/11/19
18:01
Hot Stocks
NantHealth presents new breast cancer research findings at SABCS »

NantHealth announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$30.56

0.71 (2.38%)

, AAPL

Apple

$270.71

2.09 (0.78%)

17:51
12/11/19
12/11
17:51
12/11/19
17:51
Hot Stocks
Twitter announces support for iOS Live Photos that will show as GIFs »

Earlier today Twitter…

TWTR

Twitter

$30.56

0.71 (2.38%)

AAPL

Apple

$270.71

2.09 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.